Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janick Selves

Showing results (91-100 of 114) with videos related to

Pageof 12
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 21, 2021
An unusual phenotype occurs in 15% of mismatch repair-deficient tumors and is associated with non-colorectal cancers and genetic syndromesMarion Jaffrelot, Nadim Farés, Anne Cécile Brunac, et al.
Hepatology International|May 30, 2019
Alteration of splicing factors' expression during liver disease progression: impact on hepatocellular carcinoma outcomeHualin Wang, Bouchra Lekbaby, Nadim Fares, et al.
Oncoimmunology|February 7, 2014
Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenomaKarine Poussin, Camilla Pilati, Gabrielle Couchy, et al.
Molecular Genetics and Metabolism|May 16, 2018
CCDC115-CDG: A new rare and misleading inherited cause of liver diseaseMuriel Girard, Aurélia Poujois, Monique Fabre, et al.
Cancer Medicine|February 3, 2015
PIK3CA mutations predict recurrence in localized microsatellite stable colon cancerGilles Manceau, Laetitia Marisa, Valérie Boige, et al.
Clinics and Research in Hepatology and Gastroenterology|November 13, 2020
PARP inhibitors and radiation potentiate liver cell death in vitro. Do hepatocellular carcinomas have an achilles' heel?Laetitia Gerossier, Anaëlle Dubois, Alexia Paturel, et al.
Clinics and Research in Hepatology and Gastroenterology|March 29, 2021
Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI)Jean Frédéric Blanc, Audrey Debaillon-Vesque, Gaël Roth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2021
Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon CancerLaetitia Marisa, Yuna Blum, Julien Taieb, et al.
BMJ Open Gastroenterology|May 22, 2021
Peritoneal or mesenteric tumours revealing histiocytosisFleur Cohen-Aubart, Irena Ungureanu, Jerome Razanamahery, et al.
Journal for Immunotherapy of Cancer|October 30, 2025
Efficacy of immunotherapy in gastrointestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype: an AGEO real-world studyEmily Alouani, Julien Taieb, David Tougeron, et al.
Pageof 12

Showing results (91-100 of 114) with videos related to

Sort By:
Pageof 12
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 21, 2021
An unusual phenotype occurs in 15% of mismatch repair-deficient tumors and is associated with non-colorectal cancers and genetic syndromesMarion Jaffrelot, Nadim Farés, Anne Cécile Brunac, et al.
Hepatology International|May 30, 2019
Alteration of splicing factors' expression during liver disease progression: impact on hepatocellular carcinoma outcomeHualin Wang, Bouchra Lekbaby, Nadim Fares, et al.
Oncoimmunology|February 7, 2014
Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenomaKarine Poussin, Camilla Pilati, Gabrielle Couchy, et al.
Molecular Genetics and Metabolism|May 16, 2018
CCDC115-CDG: A new rare and misleading inherited cause of liver diseaseMuriel Girard, Aurélia Poujois, Monique Fabre, et al.
Cancer Medicine|February 3, 2015
PIK3CA mutations predict recurrence in localized microsatellite stable colon cancerGilles Manceau, Laetitia Marisa, Valérie Boige, et al.
Clinics and Research in Hepatology and Gastroenterology|November 13, 2020
PARP inhibitors and radiation potentiate liver cell death in vitro. Do hepatocellular carcinomas have an achilles' heel?Laetitia Gerossier, Anaëlle Dubois, Alexia Paturel, et al.
Clinics and Research in Hepatology and Gastroenterology|March 29, 2021
Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI)Jean Frédéric Blanc, Audrey Debaillon-Vesque, Gaël Roth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2021
Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon CancerLaetitia Marisa, Yuna Blum, Julien Taieb, et al.
BMJ Open Gastroenterology|May 22, 2021
Peritoneal or mesenteric tumours revealing histiocytosisFleur Cohen-Aubart, Irena Ungureanu, Jerome Razanamahery, et al.
Journal for Immunotherapy of Cancer|October 30, 2025
Efficacy of immunotherapy in gastrointestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype: an AGEO real-world studyEmily Alouani, Julien Taieb, David Tougeron, et al.
Pageof 12